As new COVID-19 variants emerge, calls intensify to reduce gap between two vaccine doses

A study by researchers at the NCDC and the CSIR IGIB has found that the second wave surge in cases in Delhi was mainly caused by the Delta variant

FP Staff June 07, 2021 16:41:44 IST
As new COVID-19 variants emerge, calls intensify to reduce gap between two vaccine doses

Representational image. AP

There has to be a gap of 12-16 weeks between two doses of the Covishield vaccine in India after the Centre revised its guidelines in the middle of May. Around the same time though the UK cut the gap for jabs for certain populations from 12 to 8 weeks after finding that the newer variants of the novel coronavirus could blunt the effect of vaccines. Here's the latest on the optimum interval between two doses and why some have called for the gap to be reduced.

Why the gap between Doses?

There has been considerable variation witnessed in how the two doses of this vaccine have been spaced by different countries. After earlier going for a 12-week gap between two doses, UK last month said that people who receive a first dose of the Oxford-AstraZeneca vaccine can come back for their second dose within 8, and not 12, weeks. Around the same time, India upped its gap to 12 weeks.

In the early days, the decision by the UK — which was also using the Pfizer-BioNTech mRNA vaccine — to extend the gap between two doses had generated controversy before experts cited data to say that a longer gap of about 3 months was shown to be effective in drawing the best immune response. The extra gap was also seen as being helpful because countries could then vaccinate a larger number of people with at least one dose as they waited for supply chains to free up. However, it is the rise of variants that has forced a review of this gap.

Why UK reduce the gap?

Amid the rise of the B.1.617.2, or Delta, variant in the UK, the country's health authorities decided to prioritise the population aged over 50 years and those with comorbidities for vaccinations with a shortened interval. The decision was based on studies that found the Oxford-AstraZeneca and Pfizer vaccines were only 33 percent effective against the Delta variant after the first dose, but the effectiveness went up to over 88% after two doses of Pfizer with the Oxford-AstraZeneca vaccine coming in at 60 percent.

What Indian researchers have found

A study by researchers at the National Centre for Disease Control (NCDC) and the CSIR Institute of Genomics and Integrative Biology (IGIB) in New Delhi has found that the second wave surge in cases in the national capital was mainly caused by the Delta variant.

The study reportedly found that the Delta variant is 50 percent more transmissible than the Alpha variant, or B.1.1.7, or the UK variant that had caused an earlier surge in that country. It added that prior infection and partial vaccination were “insufficient impediments” for checking the spread of the Delta variant. Further, the researchers said that the Delta variant was "over-represented", that is, more common, in post-vaccination breakthrough cases.

A report by the Kolkata-based The Telegraph quoted experts who said that India should reduce the gap between doses in light of  evidence on how the new variant behaves.

In the meantime, it was reported that the Centre is looking at studying the effect of mixing shots from two different vaccines and also a single dose of Covishield jab amid a shortage in vaccine supplies.

Updated Date:

also read

India reports one lakh new COVID-19 cases today; lowest single-day tally in 61 days, says Centre
India

India reports one lakh new COVID-19 cases today; lowest single-day tally in 61 days, says Centre

The Union health ministry added that the number of deaths reported in the past 24 hours — 2,472 — is the lowest in 45 days

Explainer: What the indemnity clause is and how its waiver will accelerate COVID-19 vaccine process in India
India

Explainer: What the indemnity clause is and how its waiver will accelerate COVID-19 vaccine process in India

Given that Pfizer's mRNA vaccine is the only jab to have been approved for use in children aged 12 and 17, the 50 million doses the govt aiming to procure should be allow India vaccinate most of its children in that age group

COVID-19 crisis: Delayed second-dose may have led to Delta variant's dominance, says UK health agency
Health

COVID-19 crisis: Delayed second-dose may have led to Delta variant's dominance, says UK health agency

People who received two doses of the Pfizer vaccine may have around 88% protection against the delta variant, where it is as low as 33.5% with one dose of either Pfizer or AstraZeneca vaccine, according to Public Health England